secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0000950170-23-041606
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma Q1 net loss $4.0M; FDA aligned on Phase 3 GTX-104 trial; cash runway to Q2 2025
--------------------------------------------------------------------------------

- Net loss $4.0M ($0.54 per share) vs $4.5M ($0.61 per share) year ago.
- Cash and equivalents $21.6M at quarter end; projected runway through Q2 2025 covering potential GTX-104 NDA submission.
- FDA alignment on STRIVE-ON Phase 3 safety trial for GTX-104; first patient dosing expected Q4 2023.
- R&D expenses fell to $1.1M from $2.3M on restructuring; $1.5M severance costs incurred.
- Appointed new CMO, VP Clinical Operations, VP Program Management; expanded Scientific Advisory Board with three key opinion leaders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023041606/0000950170-23-041606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023041606/acst-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer